Compare Asian CDMOs across India, China, Japan, South Korea, and Southeast Asia. Filter by manufacturing type, regulatory approvals, and capacity for API synthesis, biologics, and drug products.
717 companies listed
Asia is the fastest-growing CDMO market, led by India (API synthesis powerhouse), China (increasingly sophisticated biologics and small molecule capabilities), South Korea (biosimilar manufacturing leader), and Japan (high-quality specialty manufacturing). Together, Asian CDMOs produce an estimated 60-80% of the world's active pharmaceutical ingredients.
India dominates small molecule API manufacturing. The country has over 3,000 pharmaceutical manufacturing facilities, many FDA-inspected, producing APIs for global generics markets. Indian CDMOs offer 30-50% cost advantages over Western alternatives for chemical synthesis. However, quality varies significantly -- due diligence on facility inspection history and quality systems is essential.
South Korea and Japan represent the premium end of Asian CDMO manufacturing. Samsung Biologics and Celltrion in South Korea have built world-class biologics facilities (up to 360,000L combined capacity). Japanese CDMOs (AGC Biologics' Chiba facility, FUJIFILM Diosynth) offer exceptional quality systems and specialized capabilities. China's WuXi Biologics and WuXi AppTec, though affected by BIOSECURE Act uncertainty, remain major global players.
Every country below has its own page with a ranked CDMO list, a country-zoomed facilities map, and the local regulatory picture. Counts are live manufacturing-site totals.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
India
Aarti Pharmalabs Limited is a leading Indian small-molecule CDMO specializing in API and drug substance development and manufacturing. They operate six manufacturing plants with two R&D centers, accredited by USFDA, EU GMP, EDQM, and KFDA. They provide services from process R&D through stability studies, scale-up, process validation, and commercial manufacturing, including high-potent/cytotoxic molecules and flow chemistry.
